https://www.selleckchem.com/pr....oducts/glumetinib.ht
51) and "great benefit" (0.88) supported responsiveness. The SQoL-6D is a promising new measure of health status in upper limb spasticity, that enables systematic assessment of the impact of this condition in relation to patients' priority treatment goals. A psychometric evaluation of SQoL-6D is presented separately. The SQoL-6D is a promising new measure of health status in upper limb spasticity, that enables systematic assessment of the impact of this condition in relation to patients' priority treatment goals. A psychometric evalu
إعجاب
علق
شارك
